Search

The presence of persulfate (S 2 O 8 ) in decontamination processes favors the oxidation of organic pollutants due to its strong oxidation power. In this research we study the photoelectrochemical generation of persulfate using five mixed metal oxides electrodes (MMO) with different compositions and its effect on the degradation of sulfamethoxazole antibiotic (SMX) by photoelectrocatalysis (PEC) and electro-oxidation (EO). By PEC, all anodes generated a higher concentration of S 2- ) in decontamination processes favors the oxidation of organic pollutants due to its strong oxidation power. In this research we study the photoelectrochemical generation of persulfate using five mixed metal oxides electrodes (MMO) with different compositions and its effect on the degradation of sulfamethoxazole antibiotic (SMX) by photoelectrocatalysis (PEC) and electro-oxidation (EO). By PEC, all anodes generated a higher concentration of S 2 than those not exposed to light. The high S 8 2- than those not exposed to light. The high S 2 O 8 2- concentration obtained by PEC was 0.150 mM using MMO [Ti/Ir/Ta] in a solution with Na 2 SO 4 100 mM applying a current density of 2 mA/cm 2 . On the other hand, the maximum concentration obtained was 0.250 mM at 30 min of electrolysis for MMO [Ti/Ir/Ta] . S 2 SO 4 50 mM and applying current density of 5 mA/cm 2 . S 2 showed the best S 8 2- production. The effect of S 2 O 5 electro-generation (using the anode with the highest and the anode with the lowest S 2 O 8 2- production. The effect of S 2 O 8 2- By EO, the degradation of SMX was partial, demonstrating that the electrophotocatalytic effect favors the generation of S 2 O 8 2- production) on the degradation of sulfamethoxazole by PEC and EO was studied using the experimental conditions with the best production of this oxidant. MMO [Ti/Ir/Ta] and MMO [Ti/Ru] were used as anodes, and it was observed that by PEC, 100% of SMX was degraded after 30 min of electrolysis using MMO [Ti/Ir/Ta] and 60 min using MMO [Ti/Ru]. By EO, the degradation of SMX was partial, demonstrating that the electrophotocatalytic effect favors the generation of S 2 O 8 2- , enhancing the degradation of SMX at short electrolysis times., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)

Objectives: To understand possible predictors of the onset of menses after gonadotropin-releasing hormone agonist treatment cessation in girls with central precocious puberty (CPP)., Methods: This exploratory post hoc analysis of a phase 3 and 4 trial of girls with CPP treated with once-monthly intramuscular leuprolide acetate examined onset of menses after treatment completion using a time-to-event analysis. Pretreatment and end-of-treatment chronologic age (CA), bone age (BA)/CA ratio, and Tanner breast stage; pretreatment menses status; and end-of-treatment BA and body mass index (BMI) were studied as potential factors influencing the onset of menses., Results: Median time to first menses after stopping treatment was 18.3 months among 35 girls (mean age at onset of treatment, 6.8 years) examined. Of 26 girls experiencing menses, 11 (42 %) menstruated at 16-21 months after stopping treatment. Most girls with pretreatment BA/CA≥1.4 started menstruating very close to 18 months after stopping treatment; those with less advanced BA/CA experienced menses at 9-18 months. End-of-treatment BA/CA≥1.2 was associated with a quicker onset of menses (14.5 vs. 18.5 months for BA/CA<1.2, p=0.006). End-of-treatment BA≥12 years predicted longer time to menses. No relationship with time to menses was observed for pretreatment menarche status, pretreatment or end-of-treatment Tanner breast stage (<3/≥3) or CA (<6/≥6 or ≤11/>11), or end-of-treatment BMI percentiles (<85.6/≥85.6 and <92.6/≥92.6)., Conclusions: Pretreatment menarche status or CA do not appear to predict onset of menses, but pre- and end-of-treatment BA/CA may be helpful in anticipating time to first menses after stopping treatment., (© 2024 Walter de Gruyter GmbH, Berlin/Boston.)